<code id='22609BFE00'></code><style id='22609BFE00'></style>
    • <acronym id='22609BFE00'></acronym>
      <center id='22609BFE00'><center id='22609BFE00'><tfoot id='22609BFE00'></tfoot></center><abbr id='22609BFE00'><dir id='22609BFE00'><tfoot id='22609BFE00'></tfoot><noframes id='22609BFE00'>

    • <optgroup id='22609BFE00'><strike id='22609BFE00'><sup id='22609BFE00'></sup></strike><code id='22609BFE00'></code></optgroup>
        1. <b id='22609BFE00'><label id='22609BFE00'><select id='22609BFE00'><dt id='22609BFE00'><span id='22609BFE00'></span></dt></select></label></b><u id='22609BFE00'></u>
          <i id='22609BFE00'><strike id='22609BFE00'><tt id='22609BFE00'><pre id='22609BFE00'></pre></tt></strike></i>

          fashion

          fashion

          author:fashion    Page View:8
          An Ozempic pen connects dots that make up the shape o a brain — coverage from STAT
          ILLUSTRATION: CHRISTINE KAO/STAT; PHOTOS: ADOBE

          Drugs like Ozempic and Wegovy — already game changers for diabetes and obesity — are being studied to treat an entirely different growing health problem: mental health illnesses, including depression and bipolar disorder.

          Early data and anecdotes suggest that this class of GLP-1 drugs could help patients feel less depressed and anxious. The treatment may also fight the decline in cognitive and executive function that many people with mental health disorders experience, like worsening memory and losing the ability to focus and plan.

          advertisement

          If further research yields positive results, it could drive even more demand for the highly popular GLP-1 treatments, which have increasingly been shown to help with problems across the body, such as heart and kidney complications. And especially if the cognitive benefits are proven out, the GLP-1 drugs would plug a critical gap in current treatments for depression, since most depression drugs help with mood, but close to none address cognitive symptoms that affect memory and attention.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          leisure time

          FDA approval of Sarepta Duchenne genetic therapy gives me hope
          FDA approval of Sarepta Duchenne genetic therapy gives me hope

          Duchennemusculardystrophyhistopathology.Dr.EdwinP.Ewing,Jr./CDCWhenIwasdiagnosedwithDuchennemuscular

          read more
          Was Amgen transparent enough on FDA's concern on cancer drug?
          Was Amgen transparent enough on FDA's concern on cancer drug?

          MarkJ.Terrill/APAmidthestunningrebukeAmgensufferedatthehandsoftheU.S.FoodandDrugAdministrationthiswe

          read more
          Bright Health sells Medicare Advantage business to Molina
          Bright Health sells Medicare Advantage business to Molina

          BrightHealthisofficiallyleavingthehealthinsurancemarket.ThecompanyhasagreedtosellitsMedicareAdvantag

          read more

          STAT Report: Patient voices and perspectives

          AdobeHealthcareisaboutmanythings—understandingandtreatingdisease,practicingmedicine,developingnewdru